Agent for application anaesthesia with antiseptic, optical-keratoprotective properties and method for use thereof in ophthalmology
SUBSTANCE: group of inventions relates to medicine and pharmacology, and can be used to produce an agent form of gel for application anaesthesia in ophthalmic surgeries. Agent contains following components, wt%: hydroxyethyl cellulose 1.2–1.8, glycerol 17–25, lidocaine hydrochloride 1.8–2.4, chlorhexidine dihydrochloride 0.03–0.07, water- balance up to 100. Also disclosed is a method of application anaesthesia in ophthalmic surgeries.
EFFECT: group of inventions enables to produce an agent possessing antiseptic, optical-keratoprotective properties without preservatives, use of which enables to achieve complete anaesthesia with no complications.
4 cl, 4 ex
SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a pain control formulation containing 4 wt % to 10 wt % of Lidocaine and 4 wt % to 10 wt % of Tetracaine, 10 wt % to 40 wt % of polyvinyl alcohol, water and sorbitan monostearate (Span 60) as an emulsifier, wherein water/PVA mass ratio makes more than 2.5, wherein the formulation provides the transdermal delivery of Lidocaine and Tetracaine, and wherein the delivery is terminated or considerably slows down when water evaporates completely, and wherein the formulation possess an initial viscosity from approximately 28,000 centipoise to approximately 828,000 centipoise, and shows a after 3 freeze-thaw cycles at least 2 times as much as the initial viscosity; the freeze-thaw cycle is determined by placing the formulation into the environment of temperature -18°C to -22°C for the time period of 48 hours and thawing the formulation at room temperature (approximately 25°C) for the time period of 48 hours.
EFFECT: invention provides the improved long-term storage of the compositions.
16 cl, 9 ex, 7 tbl, 2 dwg
SUBSTANCE: catheter is inserted into the retrobulbar space and used to introduce 2% lidocaine 1 ml and 0.5% marcaine 1 ml 15-20 minutes before applicator anchoring. The catheter is left in the retrobulbar space for 1-7 days. 10-15 minutes before removing the applicator, 2% lidocaine 0.5-1 ml and 0.5% marcaine 0.5-1 ml are introduced through the catheter. 4-6 hours after anchoring and removing the applicator, 2% lidocaine 1 ml and 0.5% marcaine 1 ml are introduced respectively additionally.
EFFECT: achieving adequate and prolonged anaesthesia in a combination with reducing a risk of a retrobulbar haematoma, eyeball puncture and visual nerve damage by eliminating the retrobulbar space re-puncture.
SUBSTANCE: after performing median sternotomy pericardial and mediastinal drainages are installed and sternum is sutured. After suturing sternum for length of its entire front surface, catheter is installed through skin counterpuncture, with 1.0-2.0 cm indent from lower wound edge. proximal end of catheter is fixed to subcutaneous-adipose cellular tissue with absorbable suture material, and distal part of catheter with cannula is fixed by suturing to skin with non-absorbable suture material. Local anaesthetic is introduced through installed catheter every 6 hours, with antibiotic being introduced every 8 hours. Introduction of medications is performed for 3-5 days.
EFFECT: method provides effective anaesthetics with simultaneous drainage of front sternum surface and skin wound due to introduction of anaesthetics and antibiotics via catheter into said zone, which additionally reduces quantity of exudative inflammatory complications in post-operative period.
2 dwg, 1 ex
SUBSTANCE: spinal anaesthesia is followed by catheterisation of an epidural space at the level of L1-L2. The spinal anaesthesia is performed at the level of L4-L5 by administering 0.5% bupivacaine. Bupivacaine is administered in a dose of 5-6 mg if the pregnant woman's height is less than 165 cm, and the dose is 6-7 mg if the pregnant woman is from 165 to 175 cm high. After the local anaesthetic is administered into the epidural space, normal saline is introduced. If the intra-abdominal pressure is ≤16 cm H2O, normal saline 15 ml is administered; if the intra-abdominal pressure is 17-21 cm H2O, an amount of normal saline is 10 ml, whereas the intra-abdominal pressure of 22-28 cm H2O requires an amount of 5 ml.
EFFECT: performing the effective spinal anaesthesia combined with reducing a probability of hypertension by dilating the epidural space preliminary in accordance with the intra-abdominal pressure.
1 tbl, 1 dwg, 2 ex
SUBSTANCE: as active component pharmaceutical composition contains dihydrochloride of 9-(2-morpholine ethyl)-2-(4-fluorophenyl)imidazo[1,2-α]benzimidasol, and as additional substances - fillers, binding, sliding and film coatings, in quantities, given in the invention formula. Composition can be made in form of solid medication form, mainly in form of tablets and capsules.
EFFECT: obtained solid medication forms satisfy the requirements of the State Pharmacopoeia.
7 cl, 2 dwg, 3 tbl, 14 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a percutaneously absorbable layer having a base and an adhesive layer which is placed on the base and which comprises an adhesive agent and a therapeutic ingredient. The adhesive agent contains a mixture of resins containing 100 portions by weight of an acrylic copolymer (A) and 0.1 to 30 portions by weight of an acrylic copolymer (B) or 0.05 to 2 portions by weight of a low-molecular polyamine compound having at least two amino groups in one molecule and non-polymerising with a polymer or an oligomer formed. The adhesive layer additionally contains an organic acid. The acrylic copolymer (A) represents an acrylic copolymer, which contains acrylic ester of (meth)acrylic acid as a main monomer ingredient and contains 3 to 45 wt % of diacetone acrylamide as a target monomer ingredient, but free from a free carboxylic group. The acrylic copolymer (B) represents an acrylic copolymer, which contains acrylic ester of (meth)acrylic acid as a main monomer ingredient and contains a primary amino group and/or carboxyhydrazidase group on side chains, but free from a free carboxylic group.
EFFECT: reducing the aging period of the adhesive layer considerably.
7 cl, 8 tbl, 39 ex
SUBSTANCE: therapeutic agent contains hypromellose, boric acid and a consistency base; it additionally contains anesthesin or lidocaine as an analgesic in an amount of 0.00001-0.5 g.
EFFECT: fixing a lubricating agent on the catheter enabling preventing mucosal injuries accompanying a drainage procedure, and eliminating side effects.
3 cl, 6 ex
SUBSTANCE: anterior chamber anaesthesia and pupil dilatation accompanying anterior eye segment surgeries experimentally involve a preoperative administration of a composition in an amount of 0.1-0.2 ml representing 0.005% 1-(3-pyrrolidinopropyl)-2-phenylimidazo[1,2-a]benzimidazole dihydrochloride into the anterior eye segment. The composition is prepared in 1% viscoelastic solution, visiton PEG.
EFFECT: prolonging anaesthetic effect and pupil dilatation with no mydriatics used.
FIELD: veterinary medicine.
SUBSTANCE: intramesovarian blockade of ovarian and cranial uterine nerves is carried out by laparotomy and administration in the mesovarium of 0.5-1% solution of novocaine or lidocaine. Blockade is carried out by inserting the needle of the syringe into the mesovarium in the vicinity of the ovarian bursa and uterine horn at an acute angle to the surface of the ovarian mesenterium to a depth of 3-4 cm. At that 3 ml of anaesthetic is administered to small breeds of dogs and fur-bearing animals, and from 3 to 9 ml of anaesthetic is administered to large and giant breeds of dogs as from one and from the opposite side of the body.
EFFECT: effective implementation of intramesovarian blockade by taking into account the anatomical and the breed features of the animal category.
SUBSTANCE: patient is laid on his/her side opposite a block region. A guide mark is a vertical line in a projection of Petit's triangle from the twelfth rib to a wing of ilium. A needle is pricked into the skin on the vertical line at 1.5-2.5cm above the wing of ilium. 0.25% Novocaine is administered in layers into the skin and subcutaneous fat. The needle is advanced into the lumbar region from back to front in the medial direction along the lateral edge of broadest muscle of back at 6-8cm. Novocaine 120ml is administered into the lower order of the lumboiliac fossa formed in this region.
EFFECT: effective and safe pain management in the given category of patients by providing the required Novocaine concentration in the retroperitoneal space.
1 dwg, 1 ex
SUBSTANCE: claimed invention relates to the field of veterinary and is intended for fighting porcine reproductive and respiratory syndrome (PRRS). The method includes the vaccination of pigs with PRRS with the provision of a reduction of hyperthermia duration and protection of lung integrity. The vaccine is obtained by a method, including mixing a live vaccine, prepared for immediate introduction, with an adjuvant-diluent (AD). The said adjuvant-diluent represents an "oil-in water" type emulsion, which contains per 100% of its weight: from 99 to 50 wt % of water and from 1 to 50 wt % of an oil adjuvant. The oil adjuvant contains per 100 % of its weight: from 1 to 95 wt % of at least one mineral oil and from 1 to 80 wt % of at least one SAS. The mineral oil represents oil of a Marcol or Draekol type. SAS represents an ester, obtained by the condensation of a fatty acid with sorbitol or mannitol.
EFFECT: obtaining the preparation for fighting reproductive and respiratory syndrome.
7 cl, 9 tbl, 1 ex
SUBSTANCE: invention represents a method for preparing a sterile nanoemulsion of perfluororganic compounds (PFOC) involving: adding a PFOC mixture to an aqueous solution of a stabilising agent; homogenising the PFOC mixture with the aqueous solution of the stabilising agent to produce a PFOC pre-emulsion; mixing the PFOC pre-emulsion with a salt-water solution to produce the PFOC nanoemulsion; keeping the PFOC nanoemulsion at a temperature from 2 to 10°C for at least 18 hours. The method can be also implemented as follows: pre-filling a circulation loop of a PFOC nanoemulsion generating plant with the aqueous solution of the stabilising agent; adding the PFOC mixture to the aqueous solution of the stabilising agent; homogenising the PFOC mixture with the aqueous solution of the stabilising agent to produce the PFOC pre-emulsion; mixing the PFOC pre-emulsion with the salt-water solution to produce the PFOC nanoemulsion.
EFFECT: higher stability of the PFOC emulsion and prolonging the storage life.
30 cl, 7 ex, 5 tbl, 1 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine and represents emulsion for prevention or treatment of syndrome of inflammatory response and other diseases. Emulsion includes oily component and water component, and oily component contains triglycerides of fish oil and medium-chain triglyceride. Said fish oil triglycerides contain omega-3 fatty acids in quantity at least 60% counted per the total weight of fatty acids of fish oil triglycerides with the total quantity of EPA and DHA constitutes at least 45% counted per the total weight of fatty acids of fish oil triglycerides. Versions of emulsion include vegetable oil in quantity to 10% counted per the total weight of oily component.
EFFECT: emulsion is stable, represents concentrated source of energy and calories, and reduces cytotoxicity of medications.
26 cl, 6 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to chemical-pharmaceutical industry and represents composition of polymeric micelle, suitable for encapsulation and suitable release of medications, which contains block-copolymers, assembled radially and have hydrophobic segment, directed inside, and hydrophilic segment, directed outside, and as block-copolymer it contains block-copolymer, which has affinity to HDL, which contains hydrophobic segment of polymeric chain, formed from hydrophobic amino acid derivative, obtained as a result of introduction of sterol residue into side chain of amino acid, and block-copolymer, which has affinity to lipoprotein, except HDL, which contains hydrophobic segment of polymeric chain, formed from hydrophobic amino acid derivative, obtained as a result of introduction of hydrophobic group, which has linear or branched structure, into side chain of amino acid.
EFFECT: invention ensures stable encapsulation of large-sized medications and their suitable release.
12 cl, 6 ex, 3 tbl, 4 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and represents a method for producing a pharmaceutical emulsion of lactulose involving the preparation stage of sieving a granular material through a sieve with a mesh size of 0.320 mm and 1.0 mm, filtering the lactulose syrup through a sieve with a mesh size of 0.320 mm and the stage of producing the emulsion with dry admixing of the granular material of the emulsion for 5-10 minutes, homogenisation of the lactulose syrup with Simethicon after the preparation stage for 10-15 minutes at a temperature of 25-30°C and at a rotation speed of 400-600 rpm followed by adding the prepared mixture of the granular material and homogenising the mixture for 30-45 minutes; the prepared emulsion is degasified under vacuum for 10 hours at a temperature of 15-25°C until a homogenous mass having a certain ratio of the ingredients is formed, that is followed by sieve filtration at a mesh size of 0.320 mm.
EFFECT: invention provides the higher physiological quality of the ready dosage form in the form of the stable non-toxic emulsion for normalising the action of the bowels, treating and preventing disbioses of various aetiologies, and recovering the normal intestinal flora following antibiotic therapy.
2 cl, 5 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a microbiologically stable pharmaceutical composition containing an active agent specified in prostaglandins, and a carrier. The carrier contains an aqueous electrochemically activated saline containing 1 to 500 mg/l of free chlorine and having an oxidation-reduction potential from +150 to +1350 mV. The active agent is present in a phase separated from the electrochemically activated saline; the electrochemically activated saline is a hypochlorite solution.
EFFECT: invention refers to using the pharmaceutical composition for treating and/or preventing dry eye syndrome and for cleansing contact lenses.
14 cl, 5 tbl, 2 ex
SUBSTANCE: invention relates to active compositions for external application. An aqueous composition suitable for local application and adapted for external application on an animal contains: dicyclanil in polymorphic form A or B; a sodium lignosulphonate hydrophilic ionic surfactant; propylene glycol or polypropylene glycol; benzyl alcohol; a flow-inducing agent; citric acid and water, wherein the composition has pH 6.44-5.02. The composition can additionally contain an antiseptic agent selected from cetrimide and chlorhexidine gluconate; an odorant selected from a group consisting of pine and citronella; a dye selected from a group consisting of water-soluble dyes, organic contrast agents and titanium dioxide.
EFFECT: invention improves stability of the aqueous composition and efficiency of preventing and treating insect and flesh fly invasion, in infected or invasion-sensitive animals, particularly sheep.
7 cl, 3 dwg, 18 tbl, 7 ex
SUBSTANCE: invention relates to the beauty industry, representing a gel-like composition for topical application, containing salicylic acid with the concentration of ca. 17 wt %, elastic collodion in the amount of 5 to 10 wt % and ethyl lactate in the amount of 20 to 25 wt %, where the elastic collodion contains 65.8 wt % diethyl ether, 24.3 wt % ethanol, 2 wt % camphor, 3 wt % castor oil and 4.9 wt % nitro-cellulose.
EFFECT: invention provides excellent stability, even drying and the formation of a uniform film.
5 cl, 1 tbl, 4 dwg
SUBSTANCE: enzyme is coated with an internal envelope of a polycation and an external envelope of a polyanion, where the polycation used is protamine or polyarginine, the polyanion used is a block-copolymer of poly(glutamic acid) and polyethylene glycol, wherein the nanoparticle has a hydrodynamic diameter in the range of 40-70 nm. The invention also relates to a dispersion which contains nanoparticles of the antioxidant enzyme superoxide dismutase for medical use in the form of polyelectrolyte complexes of the type enzyme/polycation/polyanion, and a method of producing said dispersion.
EFFECT: high stability of the enzyme in a foreign medium with preservation of the activity of the enzyme.
9 cl, 1 dwg, 1 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to medicine and deals with pharmaceutical composition, containing suspension, which includes mixture of hydrophobic medium and solid form, where solid form contains therapeutically effective quantity of octreotide and, at least, one salt of fatty acid with medium chain length, which has chain length from 6 to 14 carbon atoms, and matrix-forming polymer, selected from dextran and polyvinylpyrrolidone (PVP), with salt of fatty acid with medium chain length being present in composition in amount of 10% by weight or more. Group of inventions also deals with capsule, containing said composition, intended for peroral introduction; method of obtaining said pharmaceutical composition.
EFFECT: group of inventions relates to improvement of octreotide bioavailability.
100 cl, 39 ex, 10 dwg, 45 tbl
SUBSTANCE: invention represents a hypotensive means, which contains felodipinum as an active component, as well as target additional components: mesoporous silicon dioxide, lactose, hypromeloza. Realisation of the invention ensures the high technological efficiency of the claimed medical means production with the provision of a prolonged release of an active substance with the application of available components. Felodipinum is included into spherical particles with a highly developed mesoporous structure of silicon oxide.
EFFECT: increase of stability in storage and protection from unfavorable environmental factors.
4 cl, 4 ex